Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have received an average rating of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $27.1429.

A number of brokerages have weighed in on ZVRA. Citizens Jmp boosted their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a research note on Thursday, August 20th. BTIG Research cut their price objective on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a report on Monday, July 27th. UBS Group reiterated a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th. Finally, Canaccord Genuity Group lowered their target price on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, July 27th.

Zevra Therapeutics Stock Up 3.3%

Shares of NASDAQ ZVRA opened at $12.04 on Wednesday. The firm’s 50-day moving average price is $12.20 and its 200-day moving average price is $10.81. Zevra Therapeutics has a 52-week low of $7.16 and a 52-week high of $15.03. The company has a market cap of $714.94 million, a PE ratio of 13.09 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The firm had revenue of $39.66 million during the quarter, compared to analysts’ expectations of $33.88 million. As a group, equities research analysts anticipate that Zevra Therapeutics will post 0.72 EPS for the current fiscal year.

Insider Activity

In other news, Director Corey Michael Watton sold 12,300 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director owned 1,800 shares of the company’s stock, valued at $20,250. This represents a 87.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in Zevra Therapeutics during the fourth quarter valued at approximately $53,000. Russell Investments Group Ltd. raised its position in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after acquiring an additional 4,475 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after acquiring an additional 8,552 shares during the last quarter. Creative Planning purchased a new position in shares of Zevra Therapeutics during the 2nd quarter worth $92,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Zevra Therapeutics during the 2nd quarter worth $99,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.